Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001)

被引：0
|
作者：
Shi, Yanxia
Chen, Meiting
An, Xin
Xue, Cong
Shu, Ditian
Li, Haifeng
Huang, Riqing
Qin, Zike
Li, Yonghong
Wu, Zhiming
Yao, Kai
Liu, Zhuowei
Zhou, Fangjian
Weng, Desheng
Zhang, Xing
Xu, Ruihua
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China
[3] State Key Lab Oncol South China, Guangzhou, Peoples R China
[4] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Urol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, Canc Ctr, Guangzhou, Peoples R China
[8] Sun Yat Sen Univ, State Key Lab Oncol South China, Dept Med Melanoma & Sarcoma, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16572
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated results on multiple antigens stimulating cellular therapy (MASCT-I) in metastatic urothelial carcinoma: A randomized, open-label, phase I trial.
    Shi, Yanxia
    Chen, Meiting
    An, Xin
    Xue, Cong
    Shu, Ditian
    Li, Haifeng
    Qin, Zike
    Li, Yonghong
    Wu, Zhiming
    Li, Zhiyong
    Yao, Kai
    Liu, Zhuowei
    Zhou, Fangjian
    Zhang, Pian
    Chu, Junjun
    Zhang, Yaer
    Ma, Junxiang
    Weng, Desheng
    Zhang, Xing
    Xu, Ruihua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study
    He, Yajing
    Guo, Yabing
    Chen, Jinzhang
    Hu, Xiaoyun
    Li, Xiaoshuang
    Kong, Yanjun
    Zhang, Xiaoyong
    Zhou, Xiangjun
    Liu, Li
    Hou, Jinlin
    [J]. JOURNAL OF CANCER, 2018, 9 (08): : 1385 - 1393
  • [3] A phase I study to evaluate the safety of multi-antigen stimulated tumor specific cellular therapy (MASCT-I) in patients with advanced solid tumors
    Xu, Ruihua
    Li, Xiaoshuang
    Kong, Yanjun
    Xia, Jianchuan
    Weng, Desheng
    Zhang, Xiaoshi
    Zhang, Xing
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [4] A study of multiple-antigen specific cellular therapy in vitro combined with PD-1 antibody technology (MASCT-I) in patients with advanced solid tumors
    Zhang, X.
    Zhang, X.
    Weng, D.
    Xia, J.
    Xu, R.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [5] A phase I study to evaluate the safety of multiantigen stimulated tumor specific cell therapy (MASCT-I) in subjects with advanced gastric cancer.
    Bu, Zhaode
    Jia, Ziyu
    Ji, Ke
    Ji, Xin
    Zhang, Ji
    Wu, Xiaojiang
    Kong, Yanjun
    Zhu, Aimin
    Li, Xiaoshuang
    Ji, Jiafu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [6] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
    Takahashi, Shunji
    Uemura, Motohide
    Kimura, Tomokazu
    Kawasaki, Yoshihide
    Takamoto, Atsushi
    Yamaguchi, Akito
    Melhem-Bertrandt, Amal
    Gartner, Elaina M.
    Inoue, Takashi
    Akazawa, Rio
    Kadokura, Takeshi
    Tanikawa, Toshiki
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1056 - 1066
  • [7] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
    Shunji Takahashi
    Motohide Uemura
    Tomokazu Kimura
    Yoshihide Kawasaki
    Atsushi Takamoto
    Akito Yamaguchi
    Amal Melhem-Bertrandt
    Elaina M. Gartner
    Takashi Inoue
    Rio Akazawa
    Takeshi Kadokura
    Toshiki Tanikawa
    [J]. Investigational New Drugs, 2020, 38 : 1056 - 1066
  • [8] A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors
    Apolo, A. B.
    Mortazavi, A.
    Stein, M.
    Pal, S. K.
    Davarpanah, N.
    Parnes, H. L.
    Ning, Y. M.
    Francis, D. C.
    Cordes, L. M.
    Berniger, M.
    Steinberg, S. M.
    Monk, P.
    Lancaster, T.
    Mayer, T.
    Costello, R.
    Bottaro, D. P.
    Dahut, W. L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [9] Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
    Girardi, Daniel M.
    Niglio, Scot A.
    Mortazavi, Amir
    Nadal, Rosa
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Hadi
    Redd, Bernadette
    Steinberg, Seth M.
    Costello, Rene
    Chan, Keith S.
    Lee, Min-Jung
    Lee, Sunmin
    Yu, Yunkai
    Gurram, Sandeep
    Chalfin, Heather J.
    Valera, Vladimir
    Figg, William D.
    Merino, Maria
    Toubaji, Antoun
    Streicher, Howard
    Wright, John J.
    Sharon, Elad
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Cao, Liang
    Trepel, Jane B.
    Apolo, Andrea B.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1353 - 1362
  • [10] Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma
    Tsukamoto, Tetsuro
    Yonese, Junji
    Ohkubo, Yuhei
    Fukui, Iwao
    [J]. CANCER, 2006, 106 (11) : 2363 - 2368
12345